Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002357
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
Sponsor:
Hoechst Marion Roussel
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Multicenter Randomized Double-Blinded Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection
Status:
COMPLETED
Status Verified Date:
1997-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To obtain preliminary information on the safety tolerability and antiretroviral activity of HBY 097 alone or in combination with zidovudine AZT versus AZT alone
PER 11996 AMENDMENT AZT monotherapy arm was eliminated
PER 11996 AMENDMENT AZT monotherapy arm was eliminated
Detailed Description:
Patients are randomized to receive one of three doses of HBY 097 with or without AZT or AZT alone for 12 weeks AZT monotherapy arm eliminated per 11996 amendment All patients at a given dose level of HBY 097 must be enrolled and adequate safety data obtained before escalation in subsequent patients begins Additional patients are entered at the optimal dose of HBY 097 Patients are evaluated weekly for the first 4 weeks and then every 2 weeks for the next 9 weeks
PER AMENDMENT Enrollment to the lowest dose cohort is completed
PER AMENDMENT Enrollment to the lowest dose cohort is completed
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HBY0972001 | None | None | None |